Skip to content
StockMarketAgent
Direct answer
MCK trades against a final fair-value range of $737.34-$1,307.92, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs. Fair value range: low $737, high $1308, with mid-point at $1016.
Stock analysis

MCK MCK fair value $737–$1,308

MCK
By StockMarketAgent.AI team· supervised by
Проанализировано: 2026-05-13Следующее обновление: 2026-08-13Methodology v2.5Review: automatedArchetype: Mature compounder
View archive
Цена
$725.17
▲ +290.95 (+40.12%)
Справедливая стоимость
$1016
$737–$1308
Рекомендация
Активно покупать
confidence 79/100
Потенциал роста
+40.1%
upside to fair value
Запас прочности
$863.70
MoS level · 15%
Капитализация
$87.2B
P/E fwd 14.4
Английский по умолчаниюRU
Показываем английский источник, пока идёт перевод
Этот отчёт ещё не переведён. Обновите страницу через несколько минут, когда очередь переводов его обработает.

§1 Краткое резюме

  • Composite fair value $1,016 with high case $1,308.
  • Implied upside of 40.1% to fair value.
  • Moat 9/10 · confidence 79/100 · Mature compounder.
  • Trades below fair value with a meaningful cushion to the midpoint.
Fair value
$1,016
Margin of safety
+28.6%
Confidence
79/100
Moat
9/10

Educational analysis only — not financial advice. Always do your own due diligence.

$725.17Price
Low $737.34
Mid $1,016.12
High $1,307.92

MCK trades against a final fair-value range of $737.34-$1,307.92, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs.

  • Immense scale forming an entrenched
    Immense scale forming an entrenched oligopoly in US pharmaceutical distribution.
  • High barriers to entry due
    High barriers to entry due to extreme capital and regulatory requirements.
  • Cycle upside
    Aging demographics and expanded specialty drug approvals drive sustained volume growth.

§2 Медвежий сценарий

A stress scenario combining severe legislative pressure on drug prices with a sustained high-interest-rate environment would squeeze margins. If operating margins dip below 1.0% and the WACCWACCWeighted average cost of capital. The blended after-tax discount rate applied to free cash flows in a DCF, reflecting both equity and debt financing costs. normalizes to a higher tier, intrinsic valueIntrinsic valueThe discounted present value of all cash a business will produce over its remaining life. The theoretical anchor for fair value, computed in practice as a range across explicit assumptions. regressions toward the $737 downside boundary.

Как может разрушиться эта теза

Major Retail Network Loss

· Low

The loss of a massive retail pharmacy network customer significantly impairs revenue volume and devastates operating leverage.

FV impact
-25%

Regulatory Margin Collapse

· Medium

Aggressive legislative action on drug pricing and PBM models compresses already razor-thin operating margins below 1.0%.

FV impact
-30%

Resurgent Litigation

· Low

Unexpected expansion of opioid-related liabilities or new mass torts drain free cash flow, threatening the share buyback program.

FV impact
-15%
Сигналы раннего предупреждения для мониторинга
МетрикаТекущееТриггерный порог
Operating margins slipping below 1.2% for consecutive quarters.MonitorDeterioration versus the report thesis
Cancellation or significant reduction of the annual share repurchase program.MonitorDeterioration versus the report thesis
Loss of major customer contracts in the retail pharmacy segment.MonitorDeterioration versus the report thesis
Slowing revenue growth in the higher-margin specialty oncology segment.MonitorDeterioration versus the report thesis
Deteriorating free cash flow conversion ratios.MonitorDeterioration versus the report thesis

§3 Финансовая история

Отчёт о прибылях — последние шесть периодов
СтатьяT−0T−1T−2T−3CAGR
Период2022-03-312023-03-312024-03-312025-03-31Trend
Выручка$263.97B$276.71B$308.95B$359.05B+10.8%
Валовая прибыль$13.13B$12.36B$12.83B$13.32B+0.5%
Операционная прибыль$2.59B$4.58B$4.17B$4.82B+22.9%
Чистая прибыль$1.11B$3.56B$3.00B$3.30B+43.5%
EPS (разводнённая)$7.23$25.03$22.39$25.72+52.7%
EBITDA$2.87B$5.49B$4.68B$5.26B+22.4%
R&D
SG&A$10.54B$7.78B$8.66B$8.51B-6.9%

Баллы качества

OCF / Чистая прибыль
1.85×
>1 указывает на высокое качество прибыли
Фильтр качества учёта
Fail
Фильтр с учётом сектора
ROIC
68.7%
Доходность инвестированного капитала
Раздел 3

Numbers analysis

Денежный поток

Cash-flow quality is reflected in the OCFOperating cash flowCash generated from the company's core operations after working-capital changes but before capital expenditures. The first line of the cash-flow statement. / net incomeNet IncomeNet Income is an income-statement line item used to reconcile revenue to operating profit, pre-tax income, net income, or per-share earnings. It should be compared across periods and against peer disclosure conventions., accounting-quality, and ROICROICReturn on invested capital. Operating profit (after tax) divided by invested capital. The single best gauge of capital-efficiency. Spread over WACC = economic value created. rows above.

Распределение капитала

Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.

Индивидуальные подписчики — с §4ещё 11 разделов

Прочитайте полный анализ — ещё 11 разделов.

Competitive moat, industry cycle, peer comparison, intrinsic valuation, sensitivity, scenarios, earnings decision tree, position management, investor perspectives, scorecard, and final recommendation.

Полный отчёт по каждому покрываемому тикеру
Архив рекомендаций за 24 месяца
Брифинги списка наблюдения и алерты по изменению рекомендаций
Экспорт в PDF и DOCX на любом языке
Начать пробный период
Отмена в любое время.
FAQ

MCK — frequently asked questions

  1. Based on our latest analysis, MCK looks meaningfully undervalued. The current price is $725 versus a composite fair-value midpoint of $1016 (range $737–$1308), which implies roughly 40.1% upside to the midpoint.
Related coverage

Names readers of MCK also follow

Same archetype: mature-compounder